Genome editing of tumor specific T cells for sustained functionality in a suppressive tumor microenvironment 
Methods
In the current project, we want to genetically engineer T cells to block inhibitory pathways prior to ACT. Taking advantage of the recently developed CRISPR/Cas9 technology, genes associated with inhibitory pathways will be deleted from the genome of tumor specific T cells. These T cells will then be tested for in vivo functionality in the tumor microenvironment using a humanized mouse model. We believe that success in genetically engineering T cells to elicit sustained functionality in a suppressive tumor microenvironment would be of great importance for the further development of ACT. 
